Please login to the form below

Not currently logged in
Email:
Password:

faldaprevir

This page shows the latest faldaprevir news and features for those working in and with pharma, biotech and healthcare.

Novartis pulls EMA application for expanded Tasigna use

Novartis pulls EMA application for expanded Tasigna use

Novartis pulls EMA application for expanded Tasigna use. And Boehringer confirms it won't seek approval for faldaprevir as it exits hepatitis C. ... Boehringer drops faldaprevir. Meanwhile Boehringer confirmed it has withdrawn the application for its

Latest news

  • Boehringer pulls <b>faldaprevir</b> and exits hepatitis C market Boehringer pulls faldaprevir and exits hepatitis C market

    Boehringer pulls faldaprevir and exits hepatitis C market. Unable to challenge all-oral options from Gilead and others. ... Germany's Boehringer Ingelheim is bowing out of the race to develop oral hepatitis C virus ( HCV) therapies and has discontinued

  • Boehringer's <b>faldaprevir</b> set for rapid review in Europe Boehringer's faldaprevir set for rapid review in Europe

    Boehringer's faldaprevir set for rapid review in Europe. More competition in emerging hepatitis C market. ... Boehringer Ingelheim's new hepatitis C virus ( HCV) therapy faldaprevir could be on the market in the EU as early as the second half of 2014,

  • Boehringer says <b>faldaprevir</b> does well in Asian hepatitis C patients Boehringer says faldaprevir does well in Asian hepatitis C patients

    Boehringer says faldaprevir does well in Asian hepatitis C patients. Trial success in patients from Korea, Japan and Taiwan. ... Boehringer Ingelheim's second-generation hepatitis C virus protease inhibitor faldaprevir achieved a viral cure rate of

  • Boehringer moves interferon-free hep C regimen into phase III Boehringer moves interferon-free hep C regimen into phase III

    The combination of two of Boehringer's oral hepatitis C drugs - faldaprevir and BI 207127 - plus ribavirin achieved viral cure rate of up to 85 per cent after just 28 weeks' treatment ... Faldaprevir is a once-daily protease inhibitor while BI 207127 is

  • J&J wins FDA panel backing for hepatitis C drug J&J wins FDA panel backing for hepatitis C drug

    Other drugs emerging in the protease inhibitor class include Boehringer Ingelheim's faldaprevir, Merck's vaniprevir, Bristol-Myers Squibb's asunaprevir and AbbVie's ABT 450, which also claim superior viral cure rates and milder side

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CDM London

Brands, categories, relationships, and careers at CDM London - we want to grow them all....

Latest intelligence

Online Physician Communities
Is the pharma industry bad?
Surveys of doctors and the public suggest not...
Salary survey now open - how will you measure up?
Take part for a chance to win a Kindle Fire HD tablet...
Online Physician Communities
M3 and partners win Digital Sales Aid Award
Wins for campaign to overcome limited doctor engagement with pharma-owned websites...